KalVista Pharmaceuticals, Inc., was incorporated in Delaware on March 26, 2004. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet needs. The company has used their insights into the chemistry and biology of proteases to develop oral therapies with high selectivity, potency and bioavailability, which the company believes will make them successful drugs for the treatment of diseases. The company has used these capabilities to develop novel small molecule plasma kallikrein inhibitors for hereditary angioedema (HAE). The Company is also in the preclinical development of a new oral factor XIIa (" Factor XIIa ") inhibitor program. The company is initially advancing this project to deliver next-generation HAE therapies, which also provides an opportunity to expand into other unmet high-demand indications in the future.
